207 related articles for article (PubMed ID: 32930139)
1. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
Cetin S; Dede I
J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
[TBL] [Abstract][Full Text] [Related]
2. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
[TBL] [Abstract][Full Text] [Related]
3. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients with gallbladder carcinoma.
Liu F; Hu HJ; Ma WJ; Yang Q; Wang JK; Li FY
Medicine (Baltimore); 2019 Feb; 98(8):e14550. PubMed ID: 30813165
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
6. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer.
Tingle SJ; Severs GR; Goodfellow M; Moir JA; White SA
J Surg Oncol; 2018 Sep; 118(4):680-686. PubMed ID: 30196571
[TBL] [Abstract][Full Text] [Related]
7. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
[TBL] [Abstract][Full Text] [Related]
8. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
[TBL] [Abstract][Full Text] [Related]
9. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.
Stotz M; Gerger A; Eisner F; Szkandera J; Loibner H; Ress AL; Kornprat P; AlZoughbi W; Seggewies FS; Lackner C; Stojakovic T; Samonigg H; Hoefler G; Pichler M
Br J Cancer; 2013 Jul; 109(2):416-21. PubMed ID: 23799847
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
11. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer.
Kim WJ; Lim TW; Park PJ; Choi SB; Kim WB
ANZ J Surg; 2019 Jul; 89(7-8):E302-E307. PubMed ID: 30895709
[TBL] [Abstract][Full Text] [Related]
13. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
Guo J; Wu M; Guo L; Zuo Q
Bull Cancer; 2018 Feb; 105(2):146-154. PubMed ID: 29290332
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.
Shin K; Jung EK; Park SJ; Jeong S; Kim IH; Lee MA
World J Gastrointest Oncol; 2021 Aug; 13(8):915-928. PubMed ID: 34457195
[TBL] [Abstract][Full Text] [Related]
16. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment neutrophil-to-lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration-sensitive prostate cancer.
Salah S; Abu-Hijlih R; Abuhijla F; Tamimi F; Al-Tell A; Shahait M
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1392. PubMed ID: 34159754
[TBL] [Abstract][Full Text] [Related]
19. Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series.
Hogendorf P; Skulimowski A; Durczyński A; Kumor A; Poznańska G; Poznańska A; Oleśna A; Rut J; Øvereng Juliebø S; Szmiel A; Strzelczyk J
Pol Przegl Chir; 2020 Apr; 92(3):32-38. PubMed ID: 32759395
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour site.
Takakura K; Ito Z; Suka M; Kanai T; Matsumoto Y; Odahara S; Matsudaira H; Haruki K; Fujiwara Y; Saito R; Gocho T; Nakashiro K; Hamakawa H; Okamoto M; Kajihara M; Misawa T; Ohkusa T; Koido S
Scand J Gastroenterol; 2016; 51(5):610-7. PubMed ID: 26679084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
